Oral mucositis therapeutics currently exhibits a proliferating pipeline of 23 (excluding marketed drugs) therapeutic candidates.

OM is an inflammation of the oral mucosa, which is a common side-effect of chemotherapy and radiotherapy. The inflammation leads to the formation of ulcers and infections in mouth. It usually occurs in the patients with head and neck cancer and lasts for one week to six weeks or more. Lack of nutrition due to inability to eat and severe pain in mouth are some of the problems that occur due to OM.

According to the research, most of the pipeline drug candidates are being developed for topical administration. It has been found that the topical route is easy to use, non-invasive, and most effective method of administration.

Pre-Purchase Inquiry at: https://www.pharmaproff.com/enquiry/1243

In February 2018, the U.S. Food and Drug Administration (USFDA) granted Breakthrough Therapy designation to GC4419 to treat patients with OM. The Breakthrough Therapy provides intensive USFDA guidance for efficient drug development, and expedites the development and review process of drugs based on supporting clinical data.

Amgen Inc., Galera Therapeutics Inc., Cellceutix Corporation, Daewoong Pharmaceutical Co. Ltd., and Soligenix Inc. are some of the major companies involved in the development of drug candidates for the treatment of OM.